{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:10:10Z","timestamp":1777633810001,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016273","name":"Menarini Silicon Biosystems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.esmoop.2021.100241","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T07:03:40Z","timestamp":1629788620000},"page":"100241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD\u00a0study"],"prefix":"10.1016","volume":"6","author":[{"given":"R.","family":"de Wit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"W\u00fclfing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Carles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1.","family":"Sverrisd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Theodore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Feyerabend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Helissey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ozatilgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Geffriaud-Ricouard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100241_bib1","series-title":"EAU - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2020, European Association of Urology Guidelines","author":"Mottet","year":"2020"},{"key":"10.1016\/j.esmoop.2021.100241_bib2","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100241_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib4","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib5","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib6","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100241_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajur.2018.11.005","article-title":"Metastatic prostate cancer remains incurable, why?","volume":"6","author":"Dong","year":"2019","journal-title":"Asian J Urol"},{"key":"10.1016\/j.esmoop.2021.100241_bib8","doi-asserted-by":"crossref","first-page":"e2544","DOI":"10.1097\/MD.0000000000002544","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer: a systematic review and meta-analysis","volume":"95","author":"Yin","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.esmoop.2021.100241_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2021.100241_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2021.100241_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","article-title":"Prostate carcinogenesis: inflammatory storms","volume":"20","author":"de Bono","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2021.100241_bib12","first-page":"339","article-title":"The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: a systematic review and meta-analysis","volume":"78","author":"Russell","year":"2019","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.esmoop.2021.100241_bib13","doi-asserted-by":"crossref","first-page":"19673","DOI":"10.1038\/s41598-019-56218-z","article-title":"Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer","volume":"9","author":"Howard","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2021.100241_bib14","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2021.100241_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx502.P1791","article-title":"P1791Neutrophil lymphocyte ratio and risks of cardiovascular diseases: a systematic review and meta-analysis","volume":"38","author":"Angkananard","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.esmoop.2021.100241_bib16","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/annonc\/mdu587","article-title":"Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use","volume":"26","author":"Lorente","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdt581","article-title":"Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"Leibowitz-Amit","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdu569","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials","volume":"26","author":"van Soest","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib19","doi-asserted-by":"crossref","first-page":"e0158952","DOI":"10.1371\/journal.pone.0158952","article-title":"Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer","volume":"11","author":"Conteduca","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2021.100241_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/ijms18020380","article-title":"The role of the neutrophil to lymphocyte ratio for survival outcomes in patients with metastatic castration-resistant prostate cancer treated with abiraterone","volume":"18","author":"Boegemann","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2021.100241_bib21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clgc.2017.05.012","article-title":"Neutrophil to lymphocyte ratio in castration-resistant prostate cancer patients treated with daily oral corticosteroids","volume":"15","author":"Mehra","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmoop.2021.100241_bib22","first-page":"587","article-title":"Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate","volume":"8","author":"Yasui","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.euo.2019.01.009","article-title":"Neutrophil-to-lymphocyte ratio as a predictive marker of response to abiraterone acetate: a retrospective analysis of the COU302 study","volume":"3","author":"Loubersac","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12935-019-0785-2","article-title":"Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis","volume":"19","author":"Peng","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.esmoop.2021.100241_bib25","doi-asserted-by":"crossref","first-page":"e0158770","DOI":"10.1371\/journal.pone.0158770","article-title":"Neutrophil-to-lymphocyte ratio predicts PSA response and prognosis in prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Cao","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2021.100241_bib26","doi-asserted-by":"crossref","first-page":"e0153981","DOI":"10.1371\/journal.pone.0153981","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in localized and advanced prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Tang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2021.100241_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdv594","article-title":"A\u00a0prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","volume":"27","author":"Chi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib29","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/annonc\/mdy406","article-title":"Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer","volume":"29","author":"Armstrong","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100241_bib30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000488202","article-title":"Overall survival benefit from trastuzumab-based treatment in HER2-positive metastatic breast cancer: a retrospective analysis","volume":"41","author":"Lv","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.esmoop.2021.100241_bib31","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3389\/fimmu.2019.01710","article-title":"Neutrophils as a therapeutic target in cancer","volume":"10","author":"Granot","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2021.100241_bib32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/cancers11040564","article-title":"Tumor-associated neutrophils in cancer: Going pro","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2021.100241_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2021.100241_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2021.100241_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00280-010-1487-6","article-title":"Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy","volume":"68","author":"Shitara","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100241_bib36","doi-asserted-by":"crossref","first-page":"e0117002","DOI":"10.1371\/journal.pone.0117002","article-title":"A\u00a0multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for chinese patients with metastatic castration refractory prostate cancer","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2021.100241_bib37","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100241_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2015.12.009","article-title":"Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial","volume":"56","author":"Meisel","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100241_bib39","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(20)30449-6","article-title":"Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study","volume":"21","author":"Fizazi","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:51Z","timestamp":1761856071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921002027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2059702921002027"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100241","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD\u00a0study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100241"}}